Advanced Renal Cell Carcinoma Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Advanced Renal Cell Carcinoma Market Trends and Insights

Rising Incidence and Diagnosis of RCC

Kidney cancer incidence is rising, expanding the addressable patient pool for systemic treatment. A 2025 analysis found that incident kidney cancer cases among adults aged 65 years and older increased from 70,003 in 1990 to 203,022 in 2024. Older patients often require closer monitoring and may continue treatment across multiple lines of care. Between 20% and 30% of patients present with metastatic disease at diagnosis, while another 30% to 50% progress after local treatment.^{[1]World Health Organization, “Global Status Report on Cancer 2026,” World Health Organization, who.int} In the United States, Merck projected more than 80,000 new kidney cancer cases and more than 15,000 deaths in 2026, supporting sustained demand for advanced disease therapies.^{[2]BMC Cancer, “Rapidly Increasing Kidney Cancer Burden Among Young Adults,” BMC Cancer, springer.com}

Durable Survival Benefit From Combination Immunotherapy

Combination immunotherapy has shifted many first-line advanced RCC settings away from single-agent approaches. Pembrolizumab plus axitinib has demonstrated sustained survival benefit across IMDC risk groups in long-term follow-up. Longer survival increases the number of patients eligible for subsequent therapy after first-regimen failure, extending demand across the treatment pathway. The advanced renal cell carcinoma market benefits as effective first-line care helps patients reach later treatment settings in better clinical condition.

Expansion of Later-Line Treatment Options and Sequential Use

Later-line treatment has gained importance in the advanced renal cell carcinoma market as patients live longer after initial immunotherapy-based regimens. In February 2025, the European Commission granted conditional approval to WELIREG for advanced clear cell RCC after at least two prior lines of therapy, including a PD-1 or PD-L1 inhibitor and VEGF-targeted therapy.^{[3]Merck, “European Commission Approves Subcutaneous Administration of KEYTRUDA,” Merck, merck.com} The approval addressed a setting with limited options after earlier therapy failure and increased the focus on safety, tolerability, and sequencing. A 2026 study of metastasis-directed therapy in systemic therapy-naive oligometastatic RCC reflected growing clinical interest in combining systemic treatment with directed local treatment in selected patients.^{[4]Merck, “WELIREG Receives First European Commission Approval for Two Indications,” Merck, merck.com}

Biomarker-Enabled HIF-2α Segmentation

HIF-2α inhibition offers a differentiated approach from established VEGFR-targeted therapies and checkpoint inhibitors. VHL gene loss is common in clear cell RCC, supporting HIF-2α as a clinically relevant pathway. According to Merck, belzutifan is available in more than 30 countries for previously treated advanced RCC. In June 2026, the FDA approved pembrolizumab and belzutifan for eligible patients with clear cell RCC at intermediate-high or high risk of recurrence after nephrectomy, moving the combination into an earlier treatment stage.

Treatment-Related Toxicity and Discontinuation

Treatment-related toxicity can limit the practical use of new combinations in the advanced renal cell carcinoma market. HIF-2α inhibition can cause anemia and hypoxia, requiring monitoring that specialist oncology centers may manage more effectively than less-resourced settings. Checkpoint inhibitors can trigger immune-related adverse events, including pneumonitis, colitis, and endocrine disorders, and patients may need coordinated care across multiple medical teams. In a U.S. real-world study, inpatient admissions increased from 22% in second-line care to 32.7% in fourth-line care after immunotherapy and VEGF-based treatment failure. Dose reductions, treatment interruptions, and discontinuation can reduce the clinical and commercial value of later-line therapy.

High Cost and Unequal Reimbursement

High therapy costs remain a material barrier to adoption in the advanced renal cell carcinoma market. A U.S. real-world analysis reported total costs of USD 23,605 per patient per month across second-line, third-line, and fourth-line cohorts after immunotherapy and VEGF-based treatment failure. Cost pressure becomes more significant when patients receive multiple therapies sequentially over a longer period. A 2025 cost-effectiveness study found that toripalimab plus axitinib was not cost-effective compared with sunitinib from a U.S. third-party payer perspective. In South Korea, reimbursement criteria have lagged available treatment options in the immunotherapy era, leaving many later-line combinations without broad subsidy.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Therapy Type: Immunotherapy Leads Revenue While Targeted Agents Expand

Immunotherapy accounted for 58.88% of global revenue in 2025. PD-1 and PD-L1 inhibitors remained widely used, especially in established first-line combinations. Pembrolizumab-, nivolumab-, and ipilimumab-based regimens retained a durable role, supported by clinical evidence across risk groups. Targeted therapy is the fastest-growing segment, with the advanced renal cell carcinoma market size projected to rise at an 8.15% CAGR from 2026 to 2031.

Targeted therapy growth reflects the role of HIF-2α inhibitors and the continued use of next-generation VEGFR-TKIs. The February 2025 European approval of WELIREG for previously treated advanced clear cell RCC gave this category a defined role in European later-line care. Cytokine-based treatments retained limited use where access to newer therapies was restricted, while cytotoxic and other systemic therapies remained relevant for select refractory patients. Oral and subcutaneous forms may shift more treatment away from infusion centers, changing the balance between specialty pharmacy and hospital channels in the advanced renal cell carcinoma industry.

By Line of Therapy: First-Line Care Retains Scale While Later Lines Grow Faster

First-line treatment held 64.34% of global revenue in 2025. This position reflected the high cost of initial treatment and the broad use of immunotherapy combinations when clinicians first managed advanced disease. First-line regimens shaped subsequent care because earlier exposure to immunotherapy and VEGF-targeted agents influenced later treatment choices. Third-line and later treatment is the fastest-growing category, with the advanced renal cell carcinoma market size in this segment forecast to expand at a 9.80% CAGR from 2026 to 2031.

Later-line growth increased as survival improved in earlier stages of care. A systematic review presented at ASCO 2026 found that TKI-based regimens remained a reliable second-line option after immune checkpoint inhibitor failure. The June 2026 approval of pembrolizumab plus belzutifan in adjuvant care blurred the boundary between perioperative and metastatic treatment. Patients exposed to immunotherapy before metastatic recurrence may require different sequencing strategies, creating demand for prospective evidence after adjuvant therapy.

By Disease Subtype: Clear Cell RCC Dominates While Papillary RCC Advances

Clear cell RCC accounted for 77.89% of the advanced renal cell carcinoma market in 2025. Its leading position reflected high prevalence, broad clinical trial representation, and an extensive list of approved therapies. The subtype supported biomarker-based selection because VHL pathway changes were common. Clear cell RCC remained the main competitive setting for checkpoint inhibitors, VEGFR-TKIs, and HIF-2α inhibitors.

Papillary RCC is the fastest-growing subtype and is expected to record a 10.45% CAGR through 2031. Growth in this subtype reflects rising attention to the MET pathway and histology-based treatment selection. Other subtypes, including chromophobe, collecting duct, and hereditary RCC, remained underserved despite the significant burden associated with VHL disease. In Europe, VHL disease affects an estimated 10,000 to 15,000 people, and RCC occurs in 70% of these patients, creating a key opportunity in the advanced renal cell carcinoma industry.

By Route of Administration and Form: Oral Therapies Lead While Subcutaneous Care Gains Use

Oral administration held 55.88% of revenue in 2025, giving it the largest share within the advanced renal cell carcinoma market. Oral VEGFR-TKIs and HIF-2α inhibitors supported this position because clinicians could prescribe them for outpatient use. This format reduced reliance on infusion capacity and supported care delivery where oncology services were limited. Oral therapies also aligned with specialty pharmacy distribution models.

Subcutaneous administration is expected to grow at a 7.56% CAGR from 2026 to 2031. Subcutaneous delivery gained attention because it reduced the time needed to administer checkpoint inhibitors. The European Commission approved subcutaneous nivolumab in May 2025 for multiple solid tumors, including advanced RCC, and subcutaneous pembrolizumab in November 2025 for adult European Union indications. Intravenous administration still held substantial volume, but subcutaneous options may help oncology centers treat more patients while reducing chair-time demand.

By End User: Hospitals Hold the Largest Share While Research Institutes Grow Fastest

Hospitals and hospital pharmacies held 44.67% of advanced renal cell carcinoma market revenue in 2025. They administered many intravenous combinations in settings equipped to monitor immune-related adverse events. Tertiary referral centers concentrated the oncology expertise required for complex treatment decisions. Ambulatory surgical centers and academic institutions served smaller patient groups, including people using oral therapies or participating in trials.

Cancer research institutes are projected to grow at a 9.88% CAGR through 2031, the fastest rate among end users. Clinical trial activity and biomarker-guided enrollment supported the rising role of research institutions. These facilities provided access to investigational agents and specialized testing before treatments became widely available. Specialty pharmacies and long-term care facilities are expanding their roles as oral and subcutaneous therapies become more available, while hospitals remain central to the advanced renal cell carcinoma market.

Geography Analysis

North America held 39.89% of global advanced renal cell carcinoma market revenue in 2025. The region benefited from high disease incidence, early access to new medicines, and public and private reimbursement systems that supported treatment adoption. U.S. women had an age-standardized kidney cancer incidence rate of 8.7 per 100,000, among the highest rates reported globally. The United States received FDA approval for pembrolizumab plus belzutifan in adjuvant clear cell RCC in June 2026, while Canada and Mexico contributed less revenue but continued to expand access.

Europe was the second-largest regional area in the advanced renal cell carcinoma market, with approval pathways supporting access across 27 European Union member states after national reimbursement decisions. The European Commission conditionally approved WELIREG for advanced clear cell RCC in February 2025 and approved subcutaneous nivolumab in May 2025. Germany remained a major revenue center, while South America had lower but improving access. Brazil and Argentina expanded procurement and insurance coverage, although drug costs and fragmented reimbursement continued to limit regional uptake.

Asia-Pacific was the fastest-growing region in the advanced renal cell carcinoma market and is forecast to expand at an 8.58% CAGR from 2026 to 2031. China remained central to this growth due to rising incidence, expanding infrastructure, and locally developed regimens. In May 2026, China’s NMPA approved sintilimab plus fruquintinib for locally advanced or metastatic RCC after prior VEGFR-TKI treatment. Japan’s accelerated pathways and expanding oncology networks in India, South Korea, and Australia supported access, although South Korea still had reimbursement gaps. The Middle East and Africa remained split between early adoption in GCC states and infrastructure and supply barriers across many Sub-Saharan markets, while the Africa Medicines Agency framework offered a longer-term path to alignment.